CRO

The CRO (Contract Research Organization) theme covers companies providing outsourced R&D and clinical development services to biopharma. Core tracks include discovery and preclinical testing, clinical trial operations and site management, data management/biostatistics, regulatory and pharmacovigilance, and central lab services.The sector's total market cap is 297.53 billion HKD, with a 24h change of -0.31%. Among 9 constituents, 2 are up (22.22%) and 6 are down (66.67%). The top gainer is FANGDA HOLDING (01521), with a 24h increase of +0.87%.Tone firm with improving breadth and quality leadership. Trade leaders near term; add selectively in sync with earnings cadence and rate trends.
Name
Letzter Preis
Änderung %
Letzter Preis / Änderung %
Chart
Price Range
Aktion
01548
GENSCRIPT BIO01548
HK$16,86$2,15
+0,23 %+$0,00
HK$16,86
+0,23 %
$2,09$2,15
02359
WUXI APPTEC02359
HK$156,8$19,9
-0,12 %-$0,0
HK$156,8
-0,12 %
$19,9$20,3
02269
WUXI BIO02269
HK$38,48$4,90
-0,46 %-$0,02
HK$38,48
-0,46 %
$4,90$5,05
06127
JOINN06127
HK$24,34$3,10
-2,71 %-$0,08
HK$24,34
-2,71 %
$3,10$3,33
03759
PHARMARON03759
HK$23,30$2,97
-1,93 %-$0,05
HK$23,30
-1,93 %
$2,97$3,08
06821
ASYMCHEM06821
HK$117,60$14,99
-0,50 %-$0,07
HK$117,60
-0,50 %
$14,98$15,57
03347
TIGERMED03347
HK$37,16$4,73
-1,79 %-$0,08
HK$37,16
-1,79 %
$4,73$4,88
01873
VIVA BIOTECH01873
HK$1,30$0,16
0,00 %$0,00
HK$1,30
0,00 %
$0,16$0,16
01521
FANGDA HOLDING01521
HK$1,15$0,14
+0,87 %+$0,00
HK$1,15
+0,87 %
$0,13$0,14